OncoMatch/Colorectal Cancer (CRC)/MLH1
Colorectal Cancer (CRC)MLH1 Clinical Trials
MLH1 promoter hypermethylation — the most common cause of sporadic dMMR CRC — silences MLH1 expression in approximately 10–15% of colorectal cancers and confers MSI-H status. MLH1/PMS2 co-loss is the typical IHC pattern for sporadic dMMR, predicting response to checkpoint immunotherapy. Pembrolizumab monotherapy is the first-line standard of care for MLH1-deficient/dMMR metastatic CRC.
Top recruiting MLH1 Colorectal Cancer (CRC) trials
Ranked by phase and US site count. See all 28 trials matched to your profile →
Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC
Sun Yat-sen University
Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients
Sun Yat-sen University
PACE: PD-1 Antibody For dMMR/MSI-H Stage III Colorectal Cancer
Sun Yat-sen University
Node-Sparing Short-Course Radiotherapy Sequential Chemotherapy and PD-1 Inhibitor for Mid/Low pMMR/MSS Rectal Cancer (MODIFI-RC-II)
Sixth Affiliated Hospital, Sun Yat-sen University
Intermittent or Continuous Panitumumab Plus FOLFIRI for Left Sided RAS/B-RAF Wild-type Metastatic Colorectal Cancer
National Cancer Institute, Naples
A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer
Criterium, Inc.
Browse other molecular targets with active Colorectal Cancer (CRC) trials.